RNAi-Based Therapeutics and Target Validation

1 post / 0 new
Kristina Holmberg
Kristina Holmberg's picture
RNAi-Based Therapeutics and Target Validation

There is a short course:RNAi for beginners on June 8

Presenters: Queta K.F. Smith, Ph.D., Associate Director, Technical Communications, Thermo Fisher Scientific, Inc.
Christophe J. Echeverri, Ph.D., Chief Executive Officer & Chief Scientific Officer, Cenix BioScience GmbH
Ian MacLachlan, Ph.D., Chief Scientific Officer, Protiva Biotherapeutics Inc.
Kevin V. Morris, Ph.D., Department of Molecular Medicine, The Scripps Research Institute


Overall Introduction to RNAi Technology

From HT-RNAi Screens to in Vivo RNAi

in Vivo Delivery

Using Small RNAs to Direct Long-Term Stable Gene Silencing

Why Attend: Anyone who has started to use RNAi technology or has begun using the technology and wants to discuss issues and brainstorm with industry and academic leaders should attend this course for beginners.